GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CSPC Pharmaceutical Group Ltd (OTCPK:CHJTF) » Definitions » Capex-to-Operating-Cash-Flow

CSPC Pharmaceutical Group (CSPC Pharmaceutical Group) Capex-to-Operating-Cash-Flow : 0.00 (As of Dec. 2023)


View and export this data going back to . Start your Free Trial

What is CSPC Pharmaceutical Group Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

CSPC Pharmaceutical Group's Capital Expenditure for the three months ended in Dec. 2023 was $0.00 Mil. Its Cash Flow from Operations for the three months ended in Dec. 2023 was $0.00 Mil.

GuruFocus do not calculate Capex-to-Operating-Cash-Flow if the Cash Flow from Operations is negative.


CSPC Pharmaceutical Group Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for CSPC Pharmaceutical Group's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CSPC Pharmaceutical Group Capex-to-Operating-Cash-Flow Chart

CSPC Pharmaceutical Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.56 0.23 0.38 0.36 0.45

CSPC Pharmaceutical Group Quarterly Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of CSPC Pharmaceutical Group's Capex-to-Operating-Cash-Flow

For the Drug Manufacturers - General subindustry, CSPC Pharmaceutical Group's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CSPC Pharmaceutical Group's Capex-to-Operating-Cash-Flow Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, CSPC Pharmaceutical Group's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where CSPC Pharmaceutical Group's Capex-to-Operating-Cash-Flow falls into.



CSPC Pharmaceutical Group Capex-to-Operating-Cash-Flow Calculation

CSPC Pharmaceutical Group's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-265.128) / 585.252
=0.45

CSPC Pharmaceutical Group's Capex-to-Operating-Cash-Flow for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (0) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CSPC Pharmaceutical Group  (OTCPK:CHJTF) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


CSPC Pharmaceutical Group Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of CSPC Pharmaceutical Group's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


CSPC Pharmaceutical Group (CSPC Pharmaceutical Group) Business Description

Traded in Other Exchanges
Address
No. 226 Huanghe Street, Hebei Province, Shijiazhuang, CHN, 050035
CSPC Pharmaceutical Group listed on the Hong Kong Stock Exchange in 1994 and is one of the largest pharmaceutical companies in China. Its biggest business segment is the finished drugs segment which accounts for nearly 80% of its total revenue. Now it has a diversified pipeline portfolio in seven therapeutic areas including nervous system diseases, oncology, anti-infective to cardiovascular disease, respiratory system disease, and metabolism. CSPC also has a bulk drug product segment including vitamin C, antibiotics, and a caffeine series.

CSPC Pharmaceutical Group (CSPC Pharmaceutical Group) Headlines

From GuruFocus

Value Partners Classic Fund Comments on CSPC Pharmaceutical

By Vera Yuan Vera Yuan 07-29-2014